First National Bank Sioux Falls Buys 183 Shares of Johnson & Johnson (NYSE:JNJ)

First National Bank Sioux Falls lifted its stake in shares of Johnson & Johnson (NYSE:JNJ) by 3.5% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 5,381 shares of the company’s stock after purchasing an additional 183 shares during the quarter. Johnson & Johnson accounts for about 2.2% of First National Bank Sioux Falls’ portfolio, making the stock its 11th largest position. First National Bank Sioux Falls’ holdings in Johnson & Johnson were worth $757,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently made changes to their positions in the company. Sofos Investments Inc. grew its holdings in shares of Johnson & Johnson by 172.0% during the 1st quarter. Sofos Investments Inc. now owns 1,148 shares of the company’s stock valued at $33,000 after purchasing an additional 726 shares during the last quarter. Altshuler Shaham Ltd bought a new stake in Johnson & Johnson during the 1st quarter worth approximately $35,000. Lake Point Wealth Management grew its holdings in Johnson & Johnson by 144.4% during the 1st quarter. Lake Point Wealth Management now owns 286 shares of the company’s stock worth $38,000 after acquiring an additional 169 shares during the last quarter. Advocacy Wealth Management Services LLC grew its holdings in Johnson & Johnson by 38.2% during the 1st quarter. Advocacy Wealth Management Services LLC now owns 300 shares of the company’s stock worth $39,000 after acquiring an additional 83 shares during the last quarter. Finally, Lion Street Advisors LLC bought a new stake in Johnson & Johnson during the 1st quarter worth approximately $45,000. 68.44% of the stock is currently owned by institutional investors.

A number of equities research analysts have weighed in on the stock. Barclays boosted their target price on shares of Johnson & Johnson from $173.00 to $182.00 and gave the stock an “overweight” rating in a report on Wednesday, April 29th. Citigroup boosted their target price on shares of Johnson & Johnson from $150.00 to $165.00 and gave the stock a “buy” rating in a report on Wednesday, April 15th. Cantor Fitzgerald reissued a “buy” rating and set a $168.00 target price on shares of Johnson & Johnson in a report on Tuesday, April 28th. Raymond James boosted their target price on shares of Johnson & Johnson from $153.00 to $157.00 and gave the stock an “outperform” rating in a report on Wednesday, April 15th. Finally, Credit Suisse Group reaffirmed a “buy” rating and issued a $161.00 price objective on shares of Johnson & Johnson in a research note on Tuesday, April 28th. One analyst has rated the stock with a sell rating, four have issued a hold rating and twelve have issued a buy rating to the stock. Johnson & Johnson presently has an average rating of “Buy” and an average price target of $162.93.

Johnson & Johnson stock opened at $145.21 on Tuesday. The company has a quick ratio of 1.05, a current ratio of 1.31 and a debt-to-equity ratio of 0.41. Johnson & Johnson has a 12-month low of $109.16 and a 12-month high of $157.00. The firm’s fifty day moving average is $143.57 and its 200 day moving average is $143.88. The company has a market capitalization of $375.09 billion, a PE ratio of 19.21, a PEG ratio of 3.10 and a beta of 0.69.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, April 14th. The company reported $2.30 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.03 by $0.27. Johnson & Johnson had a net margin of 24.47% and a return on equity of 39.71%. The firm had revenue of $20.69 billion for the quarter, compared to the consensus estimate of $19.48 billion. During the same quarter in the prior year, the company posted $2.10 earnings per share. The business’s revenue was up 3.3% on a year-over-year basis. Sell-side analysts expect that Johnson & Johnson will post 7.7 EPS for the current fiscal year.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Recommended Story: How to Use the New Google Finance Tool

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.